Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 14 pages · English
Summary by 6ix AI
The report indicates that the company has exceeded a notable revenue threshold, marking a transition to a revenue-generating business model with repeat orders from various regions. Memphasys has secured multi-year contracted revenue across Europe and MENA, and has achieved regulatory approvals that support its market entry strategies. The filing outlines the company's strategic realignment and its focus on commercializing the Felix™ System, which is expected to drive future growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Memphasys
- Investor Presentation - April 2026
- MENA Orders Secured, Expanded & Operations Unaffected
- Appendix 4D - Half-year Financial Report - 31 December 2025
- Memphasys Secures TGA Approval for Felix System
- Memphasys announces successful $800,000 Capital Raising
Later from Memphasys
- ITL Orders 1000 Felix Cartridges Across MENA Markets
- South-East Asian Commercialization Agreement Secured
- Memphasys Executes Supply Agreement with Monash IVF Group
- Successful $1.2M Placement and Convertible Note Extended
- UK Market Entry & Acceleration of Commercial Expansion
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys